These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1279 related articles for article (PubMed ID: 22583038)

  • 1. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP].
    Mori M; Kato M; Koh K; Hanada R
    Rinsho Ketsueki; 2015 May; 56(5):511-3. PubMed ID: 26062675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
    Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres.
    Lakhwani S; Perera M; Fernández-Fuertes F; Ríos de Paz MA; Torres M; Raya JM; Hernández MT
    Eur J Haematol; 2017 Oct; 99(4):372-377. PubMed ID: 28759125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
    Kuter DJ; Macahilig C; Grotzinger KM; Poston SA; Wang PF; Dawson KL; Ward M
    Int J Hematol; 2015 Mar; 101(3):255-63. PubMed ID: 25586660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia.
    Al-Samkari H; Kuter DJ
    Br J Haematol; 2018 Oct; 183(2):168. PubMed ID: 29978577
    [No Abstract]   [Full Text] [Related]  

  • 7. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
    Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
    Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
    Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H
    Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
    [No Abstract]   [Full Text] [Related]  

  • 9. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
    Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
    Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
    Atkinson K
    Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia.
    Al-Samkari H; Kuter DJ
    Am J Hematol; 2018 Dec; 93(12):1501-1508. PubMed ID: 30187942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.
    Neunert CE; Rose MJ
    Blood Adv; 2019 Jun; 3(12):1907-1915. PubMed ID: 31239245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the TRAIT study.
    Cooper N; Scully M; Percy C; Nicolson PLR; Lowe G; Bagot CN; Thachil J; Grech H; Nokes T; Hill QA; Bradbury C; Talks K; Dutt T; Evans G; Pavord S; Wexler S; Charania A; Collington SJ; Ervin A; Ramscar N; Provan D
    Br J Haematol; 2024 Jun; 204(6):2442-2452. PubMed ID: 38429869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of eltrombopag after romiplostim in primary immune thrombocytopenia.
    González-Porras JR; Mingot-Castellano ME; Andrade MM; Alonso R; Caparrós I; Arratibel MC; Fernández-Fuertes F; Cortti MJ; Pascual C; Sánchez-González B; Bernat S; Fuertes-Palacio MA; Vázquez-Paganini JA; Olivera PE; Alvarez-Román MT; Jarque I; Cortés M; Martínez-Robles V; Díaz-Gálvez FJ; Calbacho M; Fernández-Miñano C; Garcia-Frade J; González-López TJ
    Br J Haematol; 2015 Apr; 169(1):111-6. PubMed ID: 25521630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombopoietin Receptor Agonist Use for Immune Thrombocytopaenia.
    Neunert CE
    Hamostaseologie; 2019 Aug; 39(3):272-278. PubMed ID: 30646404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study.
    Neunert C; Despotovic J; Haley K; Lambert MP; Nottage K; Shimano K; Bennett C; Klaassen R; Stine K; Thompson A; Pastore Y; Brown T; Forbes PW; Grace RF;
    Pediatr Blood Cancer; 2016 Aug; 63(8):1407-13. PubMed ID: 27135461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia.
    Khellaf M; Viallard JF; Hamidou M; Cheze S; Roudot-Thoraval F; Lefrere F; Fain O; Audia S; Abgrall JF; Michot JM; Dauriac C; Lefort S; Gyan E; Niault M; Durand JM; Languille L; Boutboul D; Bierling P; Michel M; Godeau B
    Haematologica; 2013 Jun; 98(6):881-7. PubMed ID: 23445876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
    Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P
    Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Romiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison.
    Cooper KL; Fitzgerald P; Dillingham K; Helme K; Akehurst R
    Int J Technol Assess Health Care; 2012 Jul; 28(3):249-58. PubMed ID: 22980701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.
    Zhang J; Liang Y; Ai Y; Xie J; Li Y; Zheng W
    Expert Opin Pharmacother; 2017 Oct; 18(15):1543-1551. PubMed ID: 28845713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.